| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | 0.22 | 0.001 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.3 | 0.002 |
| mRNA | selumetinib:GDC-0941 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | 0.098 | 0.003 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.092 | 0.004 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | 0.1 | 0.004 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.094 | 0.006 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.21 | 0.007 |
| mRNA | lovastatin | CTRPv2 | pan-cancer | AAC | -0.096 | 0.008 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.13 | 0.009 |